• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Jul 22, 2026 | Press Releases

Government acceptance initiates formal regulatory review of Entolimod under Ukraine’s Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.Ukraine Ministry of Health Accepts Entolimod for Formal Review – Following...

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Jul 20, 2026 | Press Releases

Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio’s Entolimod in cancer patients, creating a second clinical development pathway beyond Acute Radiation Syndrome. Highlights Independent...

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

Jul 14, 2026 | Press Releases

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive careSAN ANTONIO, July 14, 2026 /PRNewswire/ — Valion Bio, Inc. (Nasdaq: VBIO)...

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio’s (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Jun 25, 2026 | Press Releases

AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company’s lead candidatePositive momentum further positions Entolimod as a potential first and only treatment for GI-ARS, representing a...

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

Jun 11, 2026 | Press Releases

Emanates from the FY27 NDAA process underway in the U.S. CongressPrioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Company’s two recent briefings for senior DoW officials regarding...

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

May 19, 2026 | Press Releases

Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical CountermeasureSAN ANTONIO, May 19, 2026 /PRNewswire/ — Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.